Vor Biopharma Inc (VOR) Q1 2025 Earnings Report

Vor Biopharma reported QQ1 2025 results with no revenue and a continued heavy burn driven by R&D and G&A expenses. The company posted a net loss of approximately $32.5 million for the quarter and an adjusted EBITDA of about negative $33.3 million, with EPS of -$0.26. Cash burn yielded a net decrease in cash of roughly $31.9 million for the period, leaving cash and equivalents at $50–$52 million on the balance sheet and a net cash position of about -$19.3 million when considering total debt. The current liquidity profile is solid (current ratio ~3.88), yet the company faces a near-term runway constraint absent additional financing or clinical milestone-related cash inflows. Management’s pipeline focus remains on VOR33, an engineered hematopoietic stem cell therapy targeting AML by eliminating CD33 expression to reduce cancer cell vulnerability to CD33-directed strategies. The absence of revenue and the need for continued financing underscore the importance of forthcoming clinical readouts, potential strategic partnerships, and continued portfolio development to extend the cash runway and unlock value.